Loading...
Market
Which region will report the highest adoption rate of Hillchol (BBV131) by the end of 2025?
2
Resolution / Starting Odds
Africa • 25%
Asia • 25%
Latin America • 25%
Other • 25%
Reports from global health organizations and regional health departments
Story
Bharat Biotech Launches Hillchol (BBV131) Oral Cholera Vaccine After Successful Trials
Aug 27, 2024, 10:39 AM
Indian vaccine manufacturer Bharat Biotech has announced the launch of its novel oral cholera vaccine, Hillchol (BBV131), following successful phase 3 trials. The vaccine, developed under license from Hilleman Laboratories, aims to address the rising global cholera cases and deaths, which have been increasing since 2021. Between early 2023 and March 2024, 824,479 cases and 5,900 deaths were reported across 31 countries. The introduction of this low-cost vaccine is considered a significant milestone in global public health efforts to combat cholera.
View original story
Similar markets
North America • 25%
Europe • 25%
Asia-Pacific • 25%
Other regions • 25%
North America • 25%
Europe • 25%
Asia • 25%
Africa • 25%
North America • 25%
Europe • 25%
Asia-Pacific • 25%
Other • 25%
Sub-Saharan Africa • 25%
South Asia • 25%
Southeast Asia • 25%
Latin America • 25%
North America • 25%
Europe • 25%
Asia-Pacific • 25%
Other Regions • 25%
North America • 25%
Europe • 25%
Asia-Pacific • 25%
Other • 25%
North America • 25%
Europe • 25%
Asia-Pacific • 25%
Other regions • 25%
North America • 25%
Europe • 25%
Asia-Pacific • 25%
Other • 25%
North America • 25%
Europe • 25%
Asia-Pacific • 25%
Other • 25%
Sub-Saharan Africa • 25%
South Asia • 25%
Southeast Asia • 25%
Latin America • 25%
North America • 25%
Europe • 25%
Asia-Pacific • 25%
Other regions • 25%
North America • 25%
Europe • 25%
Asia-Pacific • 25%
Other • 25%